ASP3652 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cystitis, Interstitial
Conditions
Cystitis, Interstitial, Urinary Bladder Disease, Pain, Urologic Diseases
Trial Timeline
May 31, 2012 → Mar 18, 2014
NCT ID
NCT01613586About ASP3652 + Placebo
ASP3652 + Placebo is a phase 2 stage product being developed by Astellas Pharma for Cystitis, Interstitial. The current trial status is completed. This product is registered under clinical trial identifier NCT01613586. Target conditions include Cystitis, Interstitial, Urinary Bladder Disease, Pain.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01815684 | Phase 1 | Completed |
| NCT01613586 | Phase 2 | Completed |
| NCT01391338 | Phase 2 | Completed |
| NCT02243657 | Phase 1 | Completed |
Competing Products
19 competing products in Cystitis, Interstitial
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ferumoxytol + Gadobutrol | Lipella Pharmaceuticals | Phase 1 | 25 |
| LP-10 | Lipella Pharmaceuticals | Phase 2 | 44 |
| LP-08 80mg + Normal saline + LP-08 20mg | Lipella Pharmaceuticals | Phase 2 | 44 |
| Mirabegron + Placebo | Astellas Pharma | Phase 3 | 77 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Placebo + JNJ-42160443 | Johnson & Johnson | Phase 2 | 52 |
| Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mg | Johnson & Johnson | Approved | 85 |
| BOTOX + Placebo for BOTOX | AbbVie | Phase 2 | 52 |
| Rocuronium | Merck | Approved | 85 |
| Cidofovir | Gilead Sciences | Pre-clinical | 22 |
| PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685 | Pfizer | Phase 2 | 51 |
| Tanezumab + Tanezumab + Tanezumab + Tanezumab | Pfizer | Phase 2 | 51 |
| ERB-041 | Pfizer | Pre-clinical | 22 |
| PF-04383119 + Placebo | Pfizer | Phase 2 | 51 |
| Certolizumab pegol + Placebo | UCB | Phase 3 | 74 |
| moxifloxacin | Bayer | Phase 3 | 74 |
| Cipro (Ciprofloxacin, BAYQ3939) | Bayer | Pre-clinical | 20 |
| IW-3300 rectal foam + Placebo | Ironwood Pharmaceuticals | Phase 2 | 44 |
| MN-001 BID + MN-001 + Placebo | MediciNova | Phase 2 | 44 |